Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

50 years of hurdles and hope in anxiolytic drug discovery.

Griebel G, Holmes A.

Nat Rev Drug Discov. 2013 Sep;12(9):667-87. doi: 10.1038/nrd4075. Review.

2.

The failure of anxiolytic therapies in early clinical trials: what needs to be done.

Stewart AM, Nguyen M, Poudel MK, Warnick JE, Echevarria DJ, Beaton EA, Song C, Kalueff AV.

Expert Opin Investig Drugs. 2015 Apr;24(4):543-56. doi: 10.1517/13543784.2015.1019063. Epub 2015 Mar 1. Review.

PMID:
25727478
3.

Emerging drugs for the treatment of anxiety.

Murrough JW, Yaqubi S, Sayed S, Charney DS.

Expert Opin Emerg Drugs. 2015 Sep;20(3):393-406. doi: 10.1517/14728214.2015.1049996. Epub 2015 Jun 1. Review.

4.

Discontinued anxiolytic drugs (2009 - 2014).

Mandrioli R, Mercolini L.

Expert Opin Investig Drugs. 2015 Apr;24(4):557-73. doi: 10.1517/13543784.2014.998335. Epub 2015 Jan 5.

PMID:
25557457
5.

The age of anxiety: role of animal models of anxiolytic action in drug discovery.

Cryan JF, Sweeney FF.

Br J Pharmacol. 2011 Oct;164(4):1129-61. doi: 10.1111/j.1476-5381.2011.01362.x. Review.

6.

Future directions in anxiolytic pharmacotherapy.

Kunovac JL, Stahl SM.

Psychiatr Clin North Am. 1995 Dec;18(4):895-909. Review.

PMID:
8748388
7.

[New anxiolytic drugs: methodological issues].

Ginestet D, Corruble E.

Encephale. 1993 Nov-Dec;19(6):627-37. French.

PMID:
12404782
8.

Discovery of novel anxiolytic agents--the trials and tribulations of pre-clinical models of anxiety.

Andrews NA, Papakosta M, Barnes NM.

Neurobiol Dis. 2014 Jan;61:72-8. doi: 10.1016/j.nbd.2013.10.006. Epub 2013 Oct 10. Review.

PMID:
24120978
9.

The psychobiology of anxiolytic drug. Part 2: Pharmacological treatments of anxiety.

Argyropoulos SV, Sandford JJ, Nutt DJ.

Pharmacol Ther. 2000 Dec;88(3):213-27. Review.

PMID:
11337026
10.

Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence.

Sarris J, McIntyre E, Camfield DA.

CNS Drugs. 2013 Apr;27(4):301-19. doi: 10.1007/s40263-013-0059-9. Review. Erratum in: CNS Drugs. 2013 Aug;27(8):675. Dosage error in article text.

PMID:
23653088
11.

[Treatment of generalized anxiety: new pharmacologic approaches].

Boulenger JP.

Encephale. 1995 Nov-Dec;21(6):459-66. Review. French.

PMID:
8674471
12.

New molecular targets for antianxiety interventions.

Gorman JM.

J Clin Psychiatry. 2003;64 Suppl 3:28-35. Review.

13.

Pharmacological enhancement of fear reduction: preclinical models.

Graham BM, Langton JM, Richardson R.

Br J Pharmacol. 2011 Oct;164(4):1230-47. doi: 10.1111/j.1476-5381.2010.01175.x. Review.

14.

Therapeutic potential of kava in the treatment of anxiety disorders.

Singh YN, Singh NN.

CNS Drugs. 2002;16(11):731-43. Review.

PMID:
12383029
15.

Targeting the modulation of neural circuitry for the treatment of anxiety disorders.

Farb DH, Ratner MH.

Pharmacol Rev. 2014 Oct;66(4):1002-32. doi: 10.1124/pr.114.009126. Review.

16.

Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders.

Leonard SK, Dwyer JM, Sukoff Rizzo SJ, Platt B, Logue SF, Neal SJ, Malberg JE, Beyer CE, Schechter LE, Rosenzweig-Lipson S, Ring RH.

Psychopharmacology (Berl). 2008 May;197(4):601-11. doi: 10.1007/s00213-008-1080-4. Epub 2008 Mar 3.

PMID:
18311561
17.

Molecular targets in the treatment of anxiety.

Kent JM, Mathew SJ, Gorman JM.

Biol Psychiatry. 2002 Nov 15;52(10):1008-30. Review.

PMID:
12437941
18.

Plant-based medicines for anxiety disorders, Part 1: a review of preclinical studies.

Sarris J, McIntyre E, Camfield DA.

CNS Drugs. 2013 Mar;27(3):207-19. doi: 10.1007/s40263-013-0044-3. Review.

PMID:
23436255
19.

GABAA receptors as targets for novel anxiolytic drugs.

Rupprecht R, Eser D, Zwanzger P, Möller HJ.

World J Biol Psychiatry. 2006;7(4):231-7. Review.

PMID:
17071543
20.

Neurobiologic basis of anxiety and its treatment.

Salzman C, Miyawaki EK, le Bars P, Kerrihard TN.

Harv Rev Psychiatry. 1993 Nov-Dec;1(4):197-206. Review.

PMID:
9384849

Supplemental Content

Support Center